Replies to post #802396 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

they needed more data maturity and to file sn SAP,

Ah, and that is a huge issue. And it has been asserted by longs in the past to explain why the endpoint change and SAP was not filed long ago.

The cardinal rule on changes to a statistical based trial is that they cannot be based on any information from the trial . And now you say the SAP could not be filed w/o more trial data.

That is a prima facia admission of guilt in the frequentist court that RAs live by.

[LessIsMore]

in 2018, NICE had started the approval process, dot dot dot dot dot dot dot dot dot dot dot dot dot dot

You make way too many assumptions in this post.

NICE word for word:
This is because the company has informed NICE that, at this time, it cannot provide an evidence submission that is required for this appraisal

[LessIsMore]

As it turned out, NWBO decided not to file a evidence submission in 2018

Why didn't the dots tell you that they weren't going to file an evidence submission in 2018, on the contrary you pumped for weeks an imminent submission in August 2018?

How could you have been so wrong on this and many many others?